Last reviewed · How we verify
PQP — Competitive Intelligence Brief
marketed
Quinolone antimalarial
Plasmodium DNA gyrase and topoisomerase II
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
PQP (PQP) — Medicines for Malaria Venture. PQP is a quinolone-based antimalarial that inhibits parasite DNA gyrase and topoisomerase II, disrupting DNA replication in Plasmodium species.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PQP TARGET | PQP | Medicines for Malaria Venture | marketed | Quinolone antimalarial | Plasmodium DNA gyrase and topoisomerase II |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Quinolone antimalarial class)
- Medicines for Malaria Venture · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PQP CI watch — RSS
- PQP CI watch — Atom
- PQP CI watch — JSON
- PQP alone — RSS
- Whole Quinolone antimalarial class — RSS
Cite this brief
Drug Landscape (2026). PQP — Competitive Intelligence Brief. https://druglandscape.com/ci/pqp. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing